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Background: To investigate whether amoxillin and pefloxacin perturb lipid metabolism.
Methods: Rats were treated with therapeutic doses of each antibiotic for 5 and 10 days respectively. Twenty four
hours after the last antibiotic treatment and 5 days after antibiotic withdrawal, blood and other tissues (liver, kidney,
brain, heart and spleen) were removed from the animals after an overnight fast and analysed for their lipid
contents.
Results: Both antibiotics produced various degrees of compartment-specific dyslipidemia in the animals. While
plasma and erythrocyte dyslipidemia was characterised by up-regulation of the concentrations of the major lipids
(cholesterol, triglycerides, phospholipids and free fatty acids), hepatic and renal dyslipidemia was characterised by
cholesterogenesis and phospholipidosis. Splenic dyslipidemia was characterised by cholesterogenesis and decreased
phospholipid levels. Cardiac and brain cholesterol contents were not affected by the antibiotics. A transient
phospholipidosis was observed in the brain whereas cardiac phospholipids decreased significantly. Lipoprotein
abnormalities were reflected as down-regulation of HDL cholesterol. Furthermore, the two antibiotics increased
the activity of hepatic HMG-CoA reductase. Although erythrocyte phospholipidosis was resolved 5 days after
withdrawing the antibiotics, dyslipidemia observed in other compartments was still not reversible.
Conclusion: Our findings suggest that induction of cholesterogenesis and phospholipidosis might represent
additional adverse effects of amoxillin and pefloxacin.
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Antimicrobial agents exemplify one of the most dramatic
advances of modern medicine. Their discovery, develop-
ment and clinical use during the 20th century have de-
creased substantially the morbidity and mortality from
bacterial infections once considered incurable and lethal
[1]. Their remarkably powerful and specific activity stems
from their selectivity for targets that are either unique to
the microorganisms or much more important in them as
compared to humans.
Amoxillin [(2S, 5R, 6R)-6-{[(2R)-2-amino-2-(4-hydroxy-
phenyl)-acetyl] amino}3, 3-dimethyl-7-oxo-4-thia-1-azabi-
cyclo [3.2.0] heptane-2-carboxylic acid] and pefloxacin* Correspondence: adelad2@yahoo.com
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoqui-
noline-3-carboxylic acid] are broad spectrum anti-
microbial agents used in the treatment of typhoid
infection. While amoxillin is a β-lactam aminopenicillin
(Figure 1A), pefloxacin is a fluoroquinolone (Figure 1B).
Both are active against gram-negative bacteria. Amoxillin
acts by inhibiting the synthesis of bacterial cell walls. It in-
hibits cross-linkage between the linear peptidoglycan poly-
mer chains that make up a major component of the cell
walls of both gram-positive and gram-negative bacteria
[2]. Pefloxacin on the other hand owes it antibiotic activity
to its blocking of bacterial DNA synthesis [1,3]. It inhibits
bacterial topoisomerase II (DNA gyrase) and topoisomer-
ase IV [1,3]. Inhibition of DNA gyrase prevents the relax-
ation of positively supercoiled DNA that is required for
normal transcription and replication. Inhibition of topo-
isomerase IV interferes with separation of replicatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Chemical structure of amoxillin (A) and pefloxacin (B).
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during cell division [1,3].
Although amoxillin and pefloxacin are generally con-
sidered safe and well tolerated, they have been associated
with a wide range of adverse effects [4-7]. Adverse ef-
fects for both antibiotics range from fever, nausea, diar-
rhea and vomiting to major allergic reactions including
photo-sensitivity and skin rash [4-7]. Mental changes,
light-headedness, confusion and anxiety, have also been
reported for both antibiotics [6,8]. Tendinopathy, some-
times resulting in spontaneous rupture of tendons, has
also been reported as a side effect of treatment with pe-
floxacin [7,9,10].
Although these data about amoxillin and pefloxacin
have been known for sometime, nothing has been pub-
lished on the interaction of these antibiotics with lipids.
Interest in the interaction of drugs with lipids derives
from the observation that lipids play a major role in the
pathogenesis and progression of various disease condi-
tions. Furthermore, dyslipidemia is currently becoming a
confounding factor not only in new drug development,
but also in assessing safety of earlier approved drugs so
as to uncouple dyslipidemia from toxic manifestations of
the drug. Given these antecedents, the present study was
an attempt to investigate the effects of therapeutic doses
of amoxillin and pefloxacin on lipid metabolism in the
tissues of the rat.
Materials and methods
Chemicals
Pefloxacin was a product of Lek Pharmaceutical and
Chemical Company, Ljubljana, Slovenia, while amoxillin
was obtained from Beecham Pharmaceuticals, Brentford,
England. All other chemicals used in this study were of
the purest grade available and were obtained from British
Drug House (BDH) Chemicals Limited, Poole, England
and Sigma-Aldrich, Missouri, U. S. A.
Animals and treatment
Experimental protocols were conducted in accord with
guidelines of the Institutional Animal Care and Use
Committee and were approved by the Animal EthicalCommittee of the Department of Biochemistry, Federal
University of Agriculture, Abeokuta, Nigeria.
Sixty five male albino rats (bred in the animal holding
of Nigerian Institute of Medical Research (NIMR),
Lagos, Nigeria) with a mean body weight of 230 g were
used for the experiment. They were housed in an animal
room with normal controlled temperature (22 ± 2°C) and
a regular 12 h light–dark cycle (06:00–18:00 h). They
were allowed 14 days to acclimatise before the commence-
ment of antibiotic exposure. The animals were maintained
on a standard pellet diet.
At the start of experiments (Day 0), 5 animals were
sacrificed to obtain baseline data and the remaining ani-
mals were divided into 12 groups of 5 animals each (six
groups for pefloxacin and six groups for amoxillin). Three
groups were treated with either amoxillin (7.14 mg/kg
body weight, 8 hourly) or pefloxacin (5.71 mg/kg body
weight, 12 hourly) for 5 and 10 days respectively. The anti-
biotics were constituted in 5% dextrose and were prepared
fresh before each administration. They were administered
in a total volume of 0.1 ml. Control animals received
equivalent volume of 5% dextrose (8 hourly in amoxillin
group and 12 hourly in pefloxacin group). All drug admin-
istration was by the intraperitoneal route. During the ex-
periment, the animals were allowed free access to food
and distilled water.
At the end of the antibiotic treatment and 5 days after
the discontinuation of the antibiotics, blood was col-
lected from the animals into heparinised tubes by car-
diac puncture under light ether anaesthesia after an
overnight fast. Liver, kidney, brain, heart and spleen were
removed from the animals for biochemical analyses.
Blood samples were centrifuged to separate plasma and
red blood cells. All samples were stored at-20°C until
analysed.
Biochemical analyses
Plasma and lipoprotein lipid profiles
Determination of the major lipids (cholesterol, triglycer-
ides, phospholipids and free fatty acids) in plasma and
lipoproteins followed established procedures. Details of
these have been given in our earlier studies [11-16].
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Lipids were extracted from the organs (liver, kidney,
heart, lung, brain and spleen) as described by Folch et al.
[17] while extraction of erythrocyte lipids followed the
procedure described by Rose and Oklander [18]. After
washing with 0.05 M KCl solution, aliquots of the lipid ex-
tracts were then used for the determination of lipid pro-
files. Details of these are given as reported earlier [11-16].
Isolation of erythrocyte membrane and determination of its
lipid profile
Erythrocyte membranes were prepared according to
the method described by Hanahan and Ekholm [19].
Briefly, blood samples were centrifuged at 5000 rpm
for 15 minutes at 4°C. Plasma and buffy coat were re-
moved by careful suction and the cells were resuspended
in isotonic Tris–HCl buffer pH 7.6. After mixing by inver-
sion, the samples were recentrifuged at 5000 rpm for
15 minutes at 4°C. The supernatant was again removed by
careful suction and a few red cells were sacrificed to re-
move any remaining buffy layer. This washing procedure
was repeated twice. The washed cells were then sus-
pended in isotonic Tris–HCl buffer pH 7.6 to an approxi-
mate hematocrit of 50% and were kept on ice. The
samples were mixed gently by inversion for about 1 minute
before membrane preparation. 5 ml aliquots of the 50%
cell suspensions were transferred to 50 ml polyethylene
tubes. Thirty ml of hypotonic Tris–HCl buffer pH 7.6
were added to the cell suspension for osmotic lysis.
After allowing the tubes to stand for about 10 minutes,
they were centrifuged at 20,000 rpm for 20 minutes at
4°C. The supernatants were discarded and the pellets
resuspended in 10 ml Tris–HCl and centrifuged for
20 minutes at 20,000 rpm at 4°C. The pellets were
washed four times until the membranes were colourless.
Finally, the resultant pellets were rinsed twice with
100 μl cold Tris–HCl buffer and poured into Eppendorf
tubes. The membrane suspensions were kept frozen in
this latter buffer at-20°C. Lipids were extracted from the
membrane suspensions and determined as described for
erythrocytes [11-16].
Determination of hepatic HMG-CoA reductase activity
This was determined according to the method of Rao
and Ramakrishnan [20] by measuring the hepatic con-
centrations of HMG-CoA and mevalonate. The ratio of
HMG-CoA to mevalonate is taken as an index of the ac-
tivity of HMG-CoA reductase. An increase in this ratio
indicates inhibition of cholesterogenesis while a decrease
indicates enhanced cholesterogenesis.
Statistical analysis
Data are expressed as mean ± S.E.M. One way analysis of
variance (ANOVA) followed by Duncan Multiple RangeTest was used to analyse the results with p < 0.05 con-
sidered significant.
Results
Figures 2, 3 and 4 depict the effects of pefloxacin and
amoxillin on plasma (Figure 2), HDL (Figure 3) and LDL
+VLDL (Figure 4) lipid profiles of the animals. Adminis-
tration of the two antibiotics resulted in various degrees
of dyslipidemia in these compartments. In the plasma,
administration of the two antibiotics resulted in a signifi-
cant increase (p < 0.05) in the concentrations of all the
lipids. Comparatively, the dyslipidemia was more pro-
nounced in pefloxacin-treated animals when compared
with their amoxillin counterparts. Five days after the an-
tibiotics were discontinued, the increase was still sus-
tained, although triglyceride concentration returned to
control values in amoxillin-treated animals.
After 5 days of antibiotic treatment, HDL cholesterol de-
creased by 35% in pefloxacin-treated animals (Figure 3A)
and 63% in amoxillin-treated animals (Figure 3B) whereas
phospholipid concentrations of HDL decreased by 19%
(pefloxacin) (Figure 3E) and 18% (amoxillin) (Figure 3F)
respectively. While the decrease in HDL cholesterol was
sustained till the end of the experiment (with exception of
amoxillin-treated animals on day 10 when a significant in-
crease was observed), there was a rebound to higher HDL
phospholipid concentrations in pefloxacin-treated animals
on day 10 and 5 days after discontinuing the antibiotic
whereas this phospholipidosis was observed in amoxillin-
treated animals 5 days after discontinuing the antibiotic.
In contrast to cholesterol and phospholipids, 5 days
of antibiotic treatment resulted in a significant in-
crease (p < 0.05) in HDL triglyceride concentrations
(Figures 3C and D). While this increase amounted to
53% in pefloxacin-treated animals (Figure 3C), it was
24% in amoxillin-treated animals (Figure 3D). During
the 10 day antibiotic treatment, the increase in HDL
triglyceride was still sustained. This was however re-
versed 5 days after discontinuing the antibiotics with
the triglyceride concentration in rats treated with
amoxillin not significantly different (p >0.05) from that
of control animals whereas in pefloxacin-treated ani-
mals the increase in HDL triglyceride amounted to
63% compared with controls.
In the LDL+VLDL fraction (Figures 4A and B), admin-
istration of the two antibiotics also resulted in a signifi-
cant increase (p < 0.05) in cholesterol concentrations.
While this increase was sustained in pefloxacin-treated
animals even 5 days after discontinuing the drug, choles-
terol concentration in amoxillin-treated animals was just
about 50% of control animals 5 days after the antibiotic
was withdrawn. The two antibiotics however increased
the LDL+VLDL triglyceride throughout the course of
the experiment (Figures 4C and D). The phospholipid
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Figure 2 Effects of pefloxacin (A,C,E) and amoxillin (B,D,F) on plasma lipid profiles of the animals. Each point represents M±SEM of
5 animals.
Rotimi et al. Lipids in Health and Disease  (2015) 14:13 Page 4 of 17profile of this fraction however showed unsystematic
significant changes with the 5 days of antibiotic adminis-
tration causing a decrease, followed by an increase on
day 10 and a decrease 5 days after antibiotic withdrawal
(Figures 4E and F).
The effects of the two antibiotics on the lipid profiles
of erythrocyte as well as FFA in plasma and erythrocytes
are depicted in Figures 5 and 6. There was a significant
decrease (p < 0.05) in erythrocyte cholesterol within
5 days of antibiotic administration (Figures 5A and B).In the pefloxacin-treated animals, a 45% decrease in
erythrocyte cholesterol was observed (Figure 5A) while
in the amoxillin-treated animals, a 60% decrease in
erythrocyte cholesterol was observed (Figure 5B). A re-
bound to higher cholesterol values was however ob-
served on days 10 and 15 for both antibiotics, although
cholesterol values observed in amoxillin-treated animals
on day 15 was 15% less than control animals. In contrast
to cholesterol, the remaining erythrocyte lipids investi-
gated (triglyceride, phospholipids and free fatty acids)
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Figure 3 Effects of pefloxacin (A, C, E) and amoxillin (B, D, F) on HDL lipid profiles of the animals. Each point represents M±SEM of
5 animals.
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creases in their concentrations. Five days after antibiotic
withdrawal, erythrocyte hypertriglyceridemia and phos-
pholipidosis were resolved in pefloxacin-treated animals
(Figures 5C and E), whereas the increase observed in
erythrocyte free fatty acids was still sustained (Figures 6C
and D).
The lipid profile of the erythrocyte membrane as pre-
sented in Figure 7 also indicates that the two antibi-
otics induced a phospholipidosis in this compartment
(Figures 7E and F) and this was not resolved even 5 daysafter discontinuing the antibiotics. For cholesterol and tri-
glycerides, the slight changes (both increase and decrease)
observed during antibiotic administration had returned
to control values 5 days after withdrawing the drugs
(Figures 7A-D).
The mean values of the organ lipid profiles are shown
in Figures 8, 9, 10, 11 and 12. In all the organs, adminis-
tration of the antibiotics resulted in a significant increase
(p < 0.05) in triglyceride concentrations. The increase
ranged from 64% (kidney, Figure 9C; and brain, Figure 10C)
to 116% (spleen, Figure 11C) in pefloxacin-treated animals,
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Figure 4 Effects of pefloxacin (A,C,E) and amoxillin (B,D,F) on VLDL+LDL lipid profiles of the animals. Each point represents M±SEM of
5 animals.
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(spleen, Figure 11C) in amoxillin-treated animals. In
contrast however, both cholesterol and phospholipids
exhibited different patterns between control and antibiotic-
treated animals. In the brain (Figures 10A and B) and
heart (Figures 12A and B), antibiotic treatment did not
affect cholesterol concentrations. In the spleen, 10 days
of antibiotic treatment resulted in the induction of
cholesterogenesis (Figures 11A and B), whereas in the
kidney induction of cholesterogenesis began with
5 days of antibiotic treatment (Figures 9A and B). In
the liver, 10 days of amoxillin treatment resulted incholesterogenesis (Figure 8B), whereas pefloxacin did
not induce cholesterogenesis until 5 days after with-
drawing the drug (Figure 8A). In all the organs where
cholesterogenesis was observed, the peak of cholester-
ogenesis was observed 5 days after discontinuing the
drugs.
The mean phospholipid concentrations in the organs
as depicted in Figures 8, 9, 10, 11 and 12 indicate
that antibiotic treatment resulted in a marked hepatic
(Figures 8E and F) and renal phospholipidosis (Figures 9E
and F) and a transient brain phospholipidosis (Figures 10E
and F) whereas splenic (Figures 11E and F) and cardiac
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Figure 5 Effects of pefloxacin (A,C,E) and amoxillin (B,D,F) on erythrocyte lipid profiles of the animals. Each point represents M±SEM of
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creased. Hepatic phospholipids increased by 91% (pe-
floxacin) (Figure 8E) and 55% (amoxillin) (Figure 8F)
whereas renal phospholipids increased by 54% (pefloxacin)
(Figure 9E) and 22% (amoxillin) (Figure 9F) respectively.
The ratio of hepatic HMG-CoA/mevalonate as an
index of HMG-CoA reductase activity is depicted in
Figure 13. Within 5 days of antibiotic treatment, the
activity of HMG-CoA reductase increased by 26% (pe-
floxacin) (Figure 13A) and 46% (amoxillin) (Figure 13B)respectively. While the activity of the enzyme started
returning to control values during further administration
of amoxillin, administration of pefloxacin caused a further
increase in the activity of this enzyme. By the end of the
10 day pefloxacin administration, there was a 51% in-
crease in the activity of the enzyme. Five days after
withdrawing both antibiotics, HMG-CoA reductase ac-
tivity was 21% higher than control animals in amoxillin-
treated animals whereas it returned to control values in
pefloxacin-treated animals.
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Lipid and lipoprotein abnormalities have been shown to
play a major role in the pathogenesis and progression of
various disease conditions [21,22]. More recently, dyslip-
idemia, most especially phospholipidosis (a condition in
which there is an excessive intracellular accumulation of
phospholipids), has received considerable attention in
the drug industry. Over 250 chemicals capable of indu-
cing a phospholipidosis in cells under conditions of
in vivo administration or ex vivo incubation have been
identified [23-25]. Among them are anti-malarials like
chloroquine, anti-microbials like gentamicin and anti-
psychotics like haloperidol [23-25]. Amiodarone, an
anti-arrhythmic drug, has also been shown to induce
phospholipidosis [23-25]. Because the functional conse-
quences and clinical implications of the presence of this
condition on cellular or tissue function during drug ad-
ministration are not completely understood, phospholi-
pidosis is presently becoming a confounding factor not
only in new drug candidates, but also in assessing the
safety of numerous marketed drugs. Whether amoxillin
(an extended-spectrum penicillin) or pefloxacin (a thirdgeneration fluoroquinolone) induces any dyslipidemia,
was the basis of the present study.
The results of this study demonstrate that amoxillin
and pefloxacin at therapeutic doses, induced various de-
grees of compartment-specific dyslipidemia in the ani-
mals. While plasma and erythrocyte dyslipidemia were
characterised by up-regulation of the concentrations of
the major lipids (cholesterol, triglycerides, phospholipids
and free fatty acids {FFA}), hepatic and renal dyslipidemia
were characterised by cholesterogenesis and phospholipi-
dosis whereas splenic dyslipidemia was characterised by
cholesterogenesis and decreased phospholipid concentra-
tions. At the membrane level, phospholipidosis alone was
the hallmark of dyslipidemia in the erythrocyte membrane
while lipoprotein abnormalities were reflected as down-
regulation of HDL cholesterol and up-regulation of HDL
triglycerides and phospholipids as well as up-regulation of
LDL +VLDL cholesterol and triglycerides. Furthermore,
the two antibiotics increased triglyceride levels in all the
compartments in addition to increasing the activity of
hepatic HMG-CoA reductase. While the erythrocyte
phospholipidosis was resolved 5 days after withdrawing
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was still not resolved after withdrawing the antibiotics.
In order to avoid equilibrium, the organism must
maintain physiological levels of metabolites in its diverse
metabolic activities. Any alteration in these levels might
spell serious physiological consequences for the organ-
ism. Under physiological conditions, fat reserves of the
mammalian body are stored as droplets of triglycerides
in the adipose tissue. This triglyceride is then hydrolysedto FFA and glycerol with subsequent mobilisation of
FFA into the plasma. This hydrolysis prior to release of
FFA occurs within the adipose tissue and is catalysed by
a triglyceride lipase distinct from lipoprotein lipase
which occurs outside the adipose tissue cell [26]. Release
of FFA into the plasma is followed by FFA uptake into
tissues (including liver, heart, kidney, muscle, lung, testis
and adipose tissue), but not readily by the brain [27,28],
where they are oxidised or used in the synthesis of
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served a steady increase in plasma FFA in antibiotic-
treated animals. This suggests (an) antibiotic-induced ac-
tivation of triglyceride lipase resulting in increased tri-
glyceride hydrolysis in the adipose tissue and subsequent
increased mobilisation of the FFA into the plasma. The
physiological consequences of this elevated plasma FFA
could be viewed from the metabolic roles of FFA. While
this elevated plasma FFA should provide an immediate
substrate for triglyceride synthesis as well as the sourceof available fuel for the tissues and also the necessary
signal for tissues to oxidise them [29,30], data in
Figures 8, 9, 10, 11 and 12 indicate that while amoxillin
and pefloxacin did not inhibit the uptake of the FFA by
the tissues (they might be said to even promote uptake
of FFA), a considerable amount of the FFA was directed
towards the synthesis of triglycerides in the antibiotic-
treated animals, hence the accumulation of triglycerides
in the tissues. Data in Figure 8 also indicate that while
the liver could be said to have a limited capacity for
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Rotimi et al. Lipids in Health and Disease  (2015) 14:13 Page 11 of 17triglyceride storage, tissues like heart and kidney accu-
mulated triglyceride to about four-fold that of the liver
(Figures 8, 9, 10 and 11). This further suggests that both
amoxillin and pefloxacin induced a dysfunction of trigly-
ceride degradation resulting from insufficient mitochon-
drial ß-oxidation of FFA, hence compromising energy
production in the tissues of the antibiotic-treated ani-
mals. Although the triglyceride content of the brain
compared to other lipids in this organ is very small,administration of amoxillin and pefloxacin resulted in a
significant increase of this lipid in the brain. Since the
brain cannot take up FFA from the plasma, an
antibiotic-induced damage to the blood–brain barrier
and subsequent uptake of the plasma FFA might lead to
the triglyceride constipation observed in the brain.
The lipid composition of erythrocytes is currently be-
coming a matter of great interest because the etiology of
many diseases have been shown to have their root in
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Figure 10 Effects of pefloxacin (A,C,E) and amoxillin (B,D,F) on brain lipid profiles of the animals. Each point represents M±SEM of
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that the red cell lipid is composed almost entirely of
unesterified (free) cholesterol and phospholipid [32].
The minute amounts of cholesterol esters, the roughly
equivalent proportion of phosphatidylcholine and phos-
phatidylethanolamine, as well as the presence of phos-
phatidylserine, imprint a pattern of erythrocyte lipid
clearly different from that of the plasma environment
[33]. Despite this rather divergent lipid composition ofthe erythrocyte and its plasma environment, circulating
mature erythrocytes from mammals are limited in their
lipid metabolism in a number of respects. Firstly, there
is little evidence of de novo synthesis of lipid by the red
cell [34,35]. Secondly, in vivo and in vitro evidences sug-
gest that a major pathway for replacement of red cell
lipids is through exchange with plasma lipids [32,36,37].
Compounds like urea, acetone, alcohols and dimethyl-
sulfoxide have been shown to facilitate this exchange [32].
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Figure 11 Effects of pefloxacin (A,C,E) and amoxillin (B,D,F) on splenic lipid profiles of the animals. Each point represents M±SEM of
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in increased plasma concentrations of the major lipids,
the increase observed in erythrocyte lipids may be attrib-
uted to exchange of these lipids between plasma (lipo-
proteins) and erythrocytes [36,37]. However, since the
concentrations of the erythrocyte and plasma lipids did
not attain equal values, it is possible that the lipid levels
of erythrocytes may be composed of several pools with
more and less readily exchangeable molecules and thatamoxillin and pefloxacin promote transfer of these lipids
from these other pools into the erythrocyte [38,39].
Nikolic and his colleagues [38,40] reported a rapid rate
of exchange of lipids between HDL and erythrocytes. In
addition, Meurs and her colleagues [41] also reported
that HDL cholesterol might be an important factor in
the determination of the lifespan of erythrocytes. These
studies suggest a close association between lipids in the
HDL fraction and erythrocytes. Although our study
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Figure 12 Effects of pefloxacin (A,C,E) and amoxillin (B,D,F) on cardiac lipid profiles of the animals. Each point represents M±SEM of
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the correlation did not reach statistical significance (Data
not shown). Whether HDL might be one of these other
pools cannot be ascertained at present even though the re-
duced HDL cholesterol observed in the antibiotic-treated
animals suggests that reverse cholesterol transport was
inhibited by the two antibiotics.Lipid dynamics of the plasma have been widely studied
during various metabolic malfunctions as a result of
their involvement in vascular disorders. Cholesterol and
triglycerides have been the components of major interest
with very little attention being given to plasma phospho-
lipids as well as lipid profiles of tissues in various patholo-
gies. Our results indicate that administration of amoxillin
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lesterogenesis and phospholipidosis as well as splenic cho-
lesterogenesis. Data in Figure 2 suggest that enhanced
cholesterogenesis may be attributed to amoxillin- and
pefloxacin-induced activation of HMG-CoA reductase
(the rate-limiting enzyme in cholesterol synthesis [25].
Manipulation of the activity of HMG-CoA reductase
through alterations of its quantity (through synthesis or
degradation) and/or its intrinsic catalytic efficiency
(through phosphorylation-dephosphorylation), appears to
be the most important molecular mechanism by which
cells regulate sterol production [42-44]. While changes in
activity resulting from phosphorylation-dephosphorylation
are rapid and oftentimes transient, changes in the quantity
of enzyme protein is a relatively slow-acting, long-term
control mechanism of enzyme regulation [43]. In most
studies in which rats or cultured cells have been subjected
to a particular dietary manipulation and drugs for hours
or days, changes in HMG-CoA reductase activity were
accounted for by the alterations in the quantity of HMG-
CoA reductase protein present [42,45-47]. It is reasonable
to assume that amoxillin- and pefloxacin-induced increase
in the quantity of HMG-CoA reductase might be the
mechanism underlying the activation of this enzyme. Con-
sistent with this hypothesis was the observation of a 5 day
time lag before cholesterogenesis was induced in the
antibiotic-treated animals.
Phospholipidosis is a lipid storage disorder in which
abnormal quantities of phospholipids accumulate in
various tissues [23-25,48,49]. Xenobiotic drugs and che-
micals, as well as hormones, cofactors and other agents,
may alter the metabolism of the cell and result in phos-
pholipidosis [23-25,48,49]. The induction time may be a
few days to several months depending on the affinity of
the agent for susceptible cells [13,23-25,48]. Four major
concepts have been proposed for the mechanism of in-
duction of phospholipidosis: (1) inhibition of lysosomal
phospholipase activity-this is generally regarded as theprimary mechanism of induction, (2) inhibition of lyso-
somal enzyme transport as a result of down-regulation
of genes involved in lysosomal enzyme transport, (3) en-
hanced phospholipid biosynthesis due to enhanced FFA
availability and (4) enhanced cholesterogenesis [25]. Our
data indicate that the last two concepts might be
involved in the induction of phospholipidosis in tissues
by amoxillin and pefloxacin. Although the activity of
phospholipase was not determined in this study, an
inhibition of this enzyme by amoxillin and pefloxacin
cannot be ruled out [23]. Joshi and his colleagues [49]
also proposed that the xenobiotic could bind to phos-
pholipids making the xenobiotic-phospholipid complex
resistant to degradation by phospholipases. This mech-
anism might probably explain the phospholipidosis
observed in the erythrocyte membrane of the antibiotic-
treated animals. Since other adverse effects have been
reported for the two antimicrobials, induction of choles-
terogenesis and phospholipidosis might represent add-
itional adverse effects of amoxillin and pefloxacin.
In conclusion, the results of this study indicate
that amoxillin and pefloxacin induce a plethora of
compartment-specific dyslipidemia and these alter-
ations might contribute to the development of phos-
pholipidosis and cholesterogenesis in tissues. These
observations raise the question whether these condi-
tions are toxicologically benign processes or a sign
that cellular defence mechanisms are being over-
whelmed. Further studies going on in this laboratory
are directed towards providing insights into these
questions.
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